Return to homepagePandemic Pact

CoviNanoVax: Design of a polymeric nanoparticle-based mRNA vaccine targeting dendritic cells

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_01100

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    Salvador Borrós, Cristina Fornaguera

  • Research Location

    Spain

  • Lead Research Institution

    UNIVERSIDAD RAMON LLULL

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

CoviNanoVax arose from our previous experience in the development of polymeric nanosystems loaded with genetic material selectively targeting dendritic cells (DCs). These nanosystems will be used here as vaccines for the prevention of CoVid19. A coding mRNA for the antigenic proteins of the SARS-CoV-2 nucleocapsid will be encapsulated so that, once the nanoparticles have been injected into a healthy patient, they selectively target the DCs and transfect them. As it is an mRNA that encodes only antigenic proteins, and taking into account that the reverse transcriptase will not be present, the safety of the vaccine will be very high and, at the same time, since the mRNA is a highly antigenic macromolecule, it will develop a specific immune response to immunize healthy but susceptible people and protect them against future SARS-CoV-2 infections.